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Summary
The recent landmark Phase III clinical trial with a VEGF-specific antibody suggests that antiangiogenic therapy must be
combined with cytotoxic therapy for the treatment of solid tumors. However, there are no guidelines for optimal scheduling
of these therapies. Herewe show that VEGFR2blockade creates a “normalizationwindow”—aperiod duringwhich combined
radiation therapy gives the best outcome. This window is characterized by an increase in tumor oxygenation, which is
known to enhance radiation response. During the normalization window, but not before or after it, VEGFR2 blockade
increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick
basement membrane via MMP activation.
Introduction disorganized, and leaky vasculature and by high levels of VEGF
(Plate et al., 1992; Millauer et al., 1994). Extensive hypoxia
Attempts to combine antiangiogenic therapy with radiation ther- makes this highly malignant tumor resistant to radiation therapy
apy have produced inconsistent findings: some experimental (Rampling et al., 1994). In theory, reducing or abolishing vascular
studies have demonstrated an additive tumor growth delay, abnormalities by anti-VEGF therapy should “normalize” the tu-
others have shown a stronger, synergistic effect (Teicher et al., mor vasculature and alleviate hypoxia (Jain, 2001). On the other
1995; Mauceri et al., 1998; Lee et al., 2000; Kozin et al., 2001; hand, extensive destruction of tumor vessels by antiangiogenic
Wachsberger et al., 2003), and one study showed a compro- therapy can also hinder the delivery of oxygen and drugs, as
mised therapeutic response (Murata et al., 1997). Moreover, reported in cases where the antiangiogenic agent TNP-470 was
previous studies have disagreed on the order inwhich antiangio- combined with radiation (Murata et al., 1997) and chemotherapy
genic and radiation therapies should be given (Gorski et al., (Ma et al., 2001). It is therefore critical to determine how to
1998; Rofstad et al., 2003; Zips et al., 2003). To design an combine these therapies optimally.
optimum combination therapy, wemust unravel the mechanism Here we characterize the time course of morphological,
and timing of tumor vessel response to antiangiogenic agents functional, and molecular changes in the vasculature of or-
and use this knowledge to optimize the treatment schedule. thotopic gliomas in response to treatment with DC101, a mono-
Tumor vessels are structurally and functionally abnormal, clonal antibody against VEGFR2 (Flk-1), and the relationship
with defective endothelium, basement membrane, and pericyte between these vascular changes, tumor hypoxia, and radiation
coverage (Carmeliet and Jain, 2000; Dvorak, 2002). These ab- response. We show that it is possible to normalize the morphol-
normalities impair the delivery of oxygen and therapeutics (Jain, ogy and function of brain tumor vasculature for a period of time,
2003). One extreme example is glioblastoma multiforme, an leading to transient improvements in tumor oxygenation and
response to radiation therapy. We also provide novel insightinvariably fatal brain tumor characterized by a dilated, tortuous,
S I G N I F I C A N C E
Most antiangiogenic cancer therapies focus on the destruction of solid tumors by eradication of their supporting vasculature. However,
only combinations of antiangiogenic and chemotherapeutic agents have produced positive results in Phase III clinical trials. Preclinical
models have shown that radiation therapy is likewise often more effective when combined with antiangiogenic therapy. The success
of combination therapy may rely on the fact that antiangiogenic agents not only reduce the vessel density in tumors, but—at least
temporarily—also improve the aberrant morphology of the remaining tumor vessels, resulting in a more efficient vasculature which
is more similar to that of normal tissue. The time course of this “vascular normalization” should be taken into account when radiation
and antiangiogenic therapy are combined.
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into the role of angiopoietin-1 and matrix metalloproteinases in
the normalization process.
Results
Anti-VEGFR2 therapy produces a time window
of greatly reduced tumor hypoxia, during
which radiation therapy is most effective
We conducted a systematic evaluation of five treatment sched-
ules, using a combination of DC101 (a VEGFR2-specific mono-
clonal antibody) and  radiation to treat human glioblastoma
xenografts growing orthotopically in the mouse brain (Figure
1A). In patients, radiation (along with surgery) is the main treat-
ment for these tumors. We found that, when used as a mono-
therapy, DC101 (given at 40mg/kg on days 0, 3, and 6) produced
a small, statistically insignificant tumor growth delay of 2.5
days, while radiation (three daily fractionated doses of 7 Gy
each) significantly delayed the growth by 12.5 days. When
DC101 was given in nonoptimal combinations with radiation
(RT1, RT2, RT3, RT5), the combined therapy had no more than
an additive effect. However, giving radiation therapy on days 4
to 6 after DC101 treatment began (RT4) produced a synergistic
effect in which the tumor growth delay significantly exceeded
the expected additive effect (Figure 1A).
Because hypoxia significantly decreases the efficacy of ra-
diotherapy (Hall, 2000) and is typically severe in glioblastoma
multiforme (Rampling et al., 1994), we hypothesized that this
synergy arises from a DC101-induced improvement in tumor
oxygenation, which enhances the cytotoxic effect of radiation
treatment. Indeed, the optimum time for radiation treatment
coincided with the time of maximum tumor oxygenation: during
DC101 treatment, tumor hypoxia began to drop on day 2, was
almost abolished on day 5, and increased again by day 8 (Figure
1B). In contrast, apoptosis of tumor and vascular cells did not
coincide with the optimum treatment schedule: the apoptotic
level increased significantly on day 5 and remained the same
on day 8. Even at these times, apoptosis was moderate and Figure 1. A combination of radiation and antiangiogenic therapies is only
did not lower the cellular (nuclear) density in tumor sections synergistic during a “normalization window” when tumor hypoxia is greatly
diminished(Table 1). Thus, it is unlikely that increased tumor or vascular
cell apoptosis after DC101 accounts for the reduced tumor A: Tumor growth delay of orthotopic U87 gliomas is shown for untreated
controls (C), monotherapy with the VEGFR2-specific antibody DC101 (threehypoxia and the improved radiation response around day 5.
injections, three days apart), local radiation for three consecutive days (RT),
and five different combination schedules where radiation was given before,
Pericytes are recruited to existing tumor blood during, or after DC101 therapy (RT1–RT5; see diagram for schedules). The
vessels during the normalization window, dashed lines show the range of the expected additive effect (EAE) of DC101
and radiation. *p  0.05, compared to RT; p  0.05, compared to EAE.but not before or afterward
B: Tumor hypoxia (pimonidazole staining, red) was severe in control tumors,We set out to determine the mechanism by which VEGFR2
but decreased for a limited time during monotherapy with DC101. Hypoxiablockade transiently lowers hypoxia in glioma xenografts. We
reached a minimum at day 5, and a partial relapse occurred at day 8.
have shown that VEGF blockade can normalize the vasculature *p  0.05, compared to untreated control; p  0.05, compared to rat IgG-
in transplanted (Yuan et al., 1996; Kadambi et al., 2001; Tong treated control (day 2); #p  0.05, compared to day 2 after initiation of
DC101 therapy.et al., 2004) and spontaneous human (Willett et al., 2004) tumors,
decreasing the density, diameter, and tortuosity of vessels and
improving their integrity. It is possible that vascular normaliza-
tion can enhance the effectiveness of radiotherapy or chemo-
but the time course of this change has not been determined totherapy by improving the delivery of oxygen and drugs, respec-
date. We found that, during DC101 treatment, vessel coveragetively (Jain, 2001). We therefore asked whether the alleviation
by closely associated pericytes remained low through day 1,of tumor hypoxia is due to the transient normalization of glioma
increased markedly between days 2 and 5, and fell again byvessels by anti-VEGFR2 therapy.
day 8 (Figure 2A). Thus, the kinetics of pericyte coverage mir-It has recently been demonstrated, in both murine and hu-
rored those of tumor hypoxia.man tumors, that VEGF signal blockade increases the fraction
The mechanisms responsible for the increase in pericyteof vessels that are covered with closely attached perivascular
cells (Tong et al., 2004; Willett et al., 2004; Inai et al., 2004), coverage are largely unknown. It is widely assumed that this
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Table 1. Apoptosis in U87 gliomas after VEGFR2 blockade
Untreated IgG-treated DC101 1 DC101 2 DC101 5 DC101 8
control control day days days days
Nuclear density (nuclei/mm2) 3166  271 3214  459 3181  167 3315  405 3503  115 3142  199
Apoptotic nuclei (% of total 0.81  0.09 0.86  0.24 0.69  0.05 0.67  0.09 2.50  0.31*# 2.27  0.23*#
nuclei)
Vessel-associated apoptotic 1.63  0.59 0.91  0.69 1.59  0.30 0.94  0.44 4.76  0.90*# 4.99  1.03*#
nuclei/mm2
Quantification of nuclear density, total number of apoptotic nuclei, and vessel-associated apoptotic nuclei in control animals and at different time points
after treatment with 40 mg/kg DC101 (days 0, 3, and 6). *p  0.05, compared to untreated controls; p  0.05, compared to control-IgG treated animals
(day 2); #p  0.05, compared to DC101-treated animals (day 2).
Figure 2. VEGFR2 blockade temporarily in-
creases pericyte coverage of nonregressed tu-
mor vessels via Tie2 activation
A: The number of pericytes (NG2 staining, red)
closely associated with perfused tumor vessels
(green) increased 2 and 5 days after initiation of
DC101 treatment, compared to tumors treated
with nonspecific control-IgG. This effect was not
yet detectable on day 1 and was diminished by
day 8. Blockade of Tie2 activation by an anti-
Tie2 antibody (Tie2 AB), a Tie2-inhibiting peptide
(Tie2 peptide), or downregulation of angio-
poietin-1 expression in U87 tumor cells by siRNA
technique (siAng-1) completely abolished the
DC101-induced increase in pericyte coverage
after 2 days. In contrast, matrix metalloprotein-
ase (MMP) inhibition by GM6001 did not signifi-
cantly decrease pericyte recruitment by DC101,
but increased the number of additional, de-
tached pericytes.
B: DC101 treatment reduced the diameter of
enlarged tumor vessels, starting at day 2 of ther-
apy. In contrast, vessel length density was not
changed at day 2, but decreased progressively
at later time points. Angiograms were obtained
using dynamic multiphoton laser scanning mi-
croscopy in vivo (see Supplemental Figure S1 at
http://www.cancercell.org/cgi/content/6/6/
553/DC1/ for representative images and values).
Scale bars, 100 m. *p  0.05, compared to rat-
IgG treated control (2 days of treatment).
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increase is due to the preferential pruning of pericyte-poor ves-
sels (Benjamin et al., 1999), but if this were the case, the in-
creased coverage should be accompanied by a decrease in
vessel length per unit volume of tumor tissue; this was not
observed in our study. Two days after the initial DC101 injection,
when pericyte coverage reached its peak, we found a significant
decrease in the diameter of tumor vessels, consistent with our
previous data (Yuan et al., 1996; Kadambi et al., 2001; Tong et
al., 2004), but there was no decrease in vessel length density in
the treated mice compared to untreated controls or nonspecific
IgG-treated controls (Figures 2A and 2B). Furthermore, by day
8, extensive vascular regression had occurred (Figure 2B and
Supplemental Figure S1 at http://www.cancercell.org/cgi/
content/full/6/6/553/DC1/), but pericyte coverage had fallen to
the control level (Figure 2A), suggesting that the pericyte-cov-
ered vessels enjoyed no long-term survival advantage. These
results suggest that, rather than selectively pruning pericyte-
poor vessels, VEGFR2 blockade temporarily facilitates the re-
cruitment of pericytes to tumor vessels.
Angiopoietin-1 upregulation in the tumor cells
promotes pericyte recruitment to tumor
vessels after VEGFR2 blockade
To investigate the molecular mechanisms of pericyte recruit-
ment by VEGFR2 blockade, we used a cDNA microarray to
examine the expression of 96 human and murine genes associ-
ated with angiogenesis and vessel maturation. At the time of
peak pericyte coverage (day 2 after DC101 therapy), only two
molecules were differentially regulated more than 3-fold: human
angiopoietin-1 (Ang-1; 4.8-fold upregulation) and human Ephrin
B2 (3.8-fold upregulation). Quantitative real-time PCR using
species-specific primers confirmed only a nearly 3-fold increase
in human Ang-1 transcripts at day 2, but not at day 8 (Table 2).
Furthermore, increased synthesis of Ang-1 mRNA by cancer
cells resulted in increased deposition of Ang-1 protein in proxim-
ity to its receptor Tie2 on endothelial cells at days 2 and 5, but,
again, not at day 1 or day 8 (Figure 3A). Ang-1 upregulation at
day 5 of DC101 therapy was also confirmed by Western blot
analysis of whole tumor lysates (Figure 3B). An effect of VEGF/
VEGFR2 signaling on the Ang-1/Tie2 pathway has not previously
been shown.
Because Ang-1 is known to be involved in pericyte recruit-
ment (Stoeltzing et al., 2003; Jain, 2003), our results suggest that
Ang-1 mediates the DC101-induced recruitment of pericytes to
tumor vessels. In order to confirm the causal role of Ang-1, we
first used a Tie2-blocking antibody or peptide to block Ang-1/
Tie2 signaling. In the presence of Tie2 blockade, DC101 failed
to increase vascular pericyte coverage, consistent with our hy-
pothesis (Figure 2A). DC101 therapy also failed to decrease
mean vascular diameter (Figure 3C) when Tie-2 was blocked.
A second experiment confirmed that tumor cell-derived Ang-1
is indeed responsible for pericyte recruitment after VEGFR2
blockade: when U87 glioma cells were stably transfected with
Ang-1 siRNA (siAng-1), these cells expressed50% less Ang-1
mRNA in vitro and90% less Ang-1 protein near blood vessels
in vivo (Figure 3A). In siAng-1 tumors, DC101 therapy increased
vascular Ang-1 protein deposition insufficiently: only levels simi-
lar to those in wild-type control tumors were reached (Figure
3A). Consequently, siAng-1 tumors revealed a greatly reduced
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pericyte recruitment to tumor vessels at day 2 of DC101 therapy
(Figure 2A). Collectively, these data suggest that pericyte re-
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Figure 3. Angiopoietin-1 protein level increases
after VEGFR2 blockade, which decreases the di-
ameter of tumor vessels and induces tumor re-
oxygenation via Tie2 activation
A: Ang-1 protein (red) colocalized with perfused
vessels (green) 2 and 5 days after initiation of
DC101 therapy. In contrast, low levels of Ang-1
near perfused vessels was observed in control
tumors, at day 1 and at day 8 after initiation of
DC101 therapy, and when Ang-1 protein pro-
duction was blocked in tumor cells by siRNA
transfection (siAng-1).
B: Western blot analysis confirmed increased
Ang-1 expression in whole tumor lysates at day 5.
C: Treatment with an anti-Tie2 antibody (Tie2
AB) inhibited the DC101-induced decrease in
mean vessel diameter after 2 days.
D: Tie2 inhibition with an Tie2 peptide also dimin-
ished tumor reoxygenation at day 5 of DC101
therapy.
Scale bars, 100 m. *p  0.05, compared to un-
treated control; p 0.05, compared to rat-IgG-
treated control (day 2); #p  0.05, compared
to day 2 after initiation of DC101 therapy.
cruitment by tumor cell-derived Ang-1 plays a critical role in the ported in other tumor models (Baluk et al., 2003), and has also
been observed in diabetes mellitus and neurodegenerative dis-normalization of vessel diameter after VEGFR2 blockade.
Ang-1 is also known to reduce vascular permeability of the eases, where it was linked to impaired vascular function (Tsili-
bary, 2003; Farkas et al., 2000). In addition, BM thickening isblood-brain barrier (Lee et al., 2003). However, although we
found that vascular permeability to albumin was reduced seen in human glioblastoma multiforme: a majority (18 out of
30) of glioblastoma patients show tumor vessels characterizedthroughout the entire course of DC101 treatment (Supplemental
Figure S1F), this reduction was independent of the kinetics of by a pathologically thick BM (Figure 4B).
Ang-1 expression or pericyte coverage, which suggests that it
was not mediated by Ang-1 exclusively. VEGFR2 blockade degrades basement membrane
We finally sought to demonstrate that vascular stabilization via activation of matrix metalloproteinases
induced by angiopoietin-1 indeed results in better tumor oxy- Because Tie-2 blockade did not affect the thinning of tumor
genation after VEGFR2 blockade. When the Tie2 receptor was vessel BM, indicating that increased pericyte involvement was
blocked, reduction in tumor hypoxia at day 5 was diminished not responsible (Figure 5A), we investigated the possibility that
after DC101 therapy (Figure 3D), indicating a causal link between reduced production and/or increased degradation of BM com-
Ang-1-mediated vascular normalization and vascular function. ponents was responsible for the change in BM morphology.
Indeed, the mRNA expression of murine collagen IV was re-
duced after DC101 treatment (Table 2). However, increasedThe abnormally thick basement membrane
of brain tumor vessels is reduced during activity of the matrix metalloproteinases (MMPs) -2 and -9,
which can rapidly degrade collagen IV and other componentsthe normalization window
We also observed dramatic changes in the vascular basement of the BM, may be functionally more important. In contrast,
MMP-9 was shown to be downregulated by inhibition ofmembrane (BM) 2 to 5 days after DC101 injection. Whereas
vessels in control tumors had an aberrantly thick, multilayer BM VEGFR2 (Sweeney et al., 2002) or VEGFR1 (Hiratsuka et al.,
2002) signaling in murine lung endothelial cells in vivo and(as indicated by collagen IV staining), DC101 treatment reduced
BM thickness on days 2 and 5, and (to a lesser degree) on day in vitro. In U87 gliomas, we found that MMP-2 and -9 proteins
were expressed around vessels at equivalent levels in control8, but not on day 1 (Figure 4A). Similar changes occurred in the
other major BM components (laminin, entactin, perlecan). The and treated animals (not shown), so we investigated whether
posttranslational MMP activation occurs after VEGFR2 block-BM is shared by endothelial cells and pericytes and is a major
component of the vascular wall. BM thickening has been re- ade. Surprisingly, using in situ zymography, we discovered an
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Figure 4. VEGFR2 blockade thins the abnormally thick basement membrane (BM) of tumor vessels
A: The vascular basement membrane (collagen IV staining, red) was thin and closely associated with perfused vessels (green) in normal brain, but appeared
thickened, disorganized, and occasionally multilayered in control tumors. DC101 reduced the mean basement membrane thickness at day 2 and 5. This
effect was not visible before day 2, and was diminished by day 8 of DC101 therapy. *p  0.05, compared to untreated control; p  0.05, compared to
control treated with rat nonspecific IgG (day 2); #p  0.05, compared to day 2 after initiation of DC101 therapy.
B: A majority (18/30) of glioblastoma patients showed tumor vessels with a thickened basement membrane.
Scale bars, 100 m.
increase in collagenase IV activity at the vascular wall 2 days Munn, 2000): it has been shown to increase pericyte coverage,
and several studies indicate that this process implies vesselafter DC101 therapy (Figure 5B). Furthermore, coadministration
maturation and improved vascular function (Hawighorst et al.,of a broad-spectrum inhibitor of the matrix metalloproteinases
2002; Stoeltzing et al., 2003). Furthermore, even in the complete(MMPs), GM6001, completely abolished the DC101-induced
absence of mural cells, recombinant Ang-1 can restore a hierar-BM thinning (Figure 5C).
chical vasculature and inhibit retinal edema and hemorrhage
(Uemura et al., 2002). It also reduces vascular permeability inDiscussion
the skin (Thurston et al., 1999), tumors (Stoeltzing et al., 2003),
and an in vitro blood-brain barrier model by maturation of endo-Collectively, these results demonstrate that VEGFR2 blockade
thelial cells (Lee et al., 2003). Consistent with these findings,can temporarily normalize tumor vessel structure (pericyte and
the increased expression of the naturally occurring Ang-1 antag-basement membrane coverage), leading to improved vascular
onist, Ang-2, in glioma vessels is associated with their destabili-function (tumor oxygenation) and enhanced response to radia-
zation (Holash et al., 1999) and is negatively correlated withtion therapy. Figure 6A illustrates the time course of these
pericyte coverage, both in human glioblastoma specimenschanges, while the proposed underlyingmolecular mechanisms
(Stratmann et al., 1998) and experimental gliomas (Koga et al.,are summarized in Figure 6B.
2001). Here we show that an increase in the Ang-1/Ang-2 ratioOur findings suggest several important changes to the exist-
with activated Ang-1/Tie2 signaling after VEGFR2 blockade re-ing paradigm. Contrary to the view that the primary result of
cruits pericytes to tumor vessels and subsequently reducesanti-VEGF treatment is to prune tumor vessels that are devoid
their enlarged diameter, demonstrating a profound effect of this
of pericytes (Benjamin et al., 1999), we show that, during the phenomenon on the tumor vessel network. Therefore, Ang-1
normalization window in brain tumors, VEGFR2 blockade tem- upregulation acts synergistically with the direct effects of
porarily recruits pericytes to blood vessels by activating Ang-1/ VEGFR2 blockade on endothelial cells to normalize brain tumor
Tie2 signaling. These fortified vessels become more efficient, vessels.
enhancing oxygen delivery to the tumor. Ang-1 upregulation after VEGFR2 blockade is not specific
Ang-1 has been implicated in facilitating interaction between for brain tumor vessels: in subcutaneously growing MCaIV
endothelial cells and pericytes during angiogenesis (Jain, 2003). mammary carcinomas, DC101 therapy likewise resulted in in-
Others have shown that expression of Ang-1 is restricted to creased expression of Ang-1 and its vascular deposition (Sup-
cancer cells in human glioblastoma multiforme (Stratmann et plemental Figure S2) at a time of increased pericyte coverage
al., 1998) and glioma animal models (Holash et al., 1999). Our (Tong et al., 2004). However, neither Ang-1 expression nor peri-
results extend this finding, showing that Ang-1 protein produced cyte coverage was changed in normal vessels of the brain,
by tumor cells is found mainly in the vicinity of vessels, where heart, and kidney during DC101 therapy (unpublished data),
it is sequestered by its endothelial receptor Tie2. Ang-1 has indicating that Ang-1 upregulation after VEGFR2 blockade is
specific for the tumor environment.well-defined, substantial effects on the vasculature (Jain and
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Figure 5. Basement membrane thinning after VEGFR2 blockade results from
increased degradation by matrix metalloproteinases
A: Interference with Tie-2 signaling did not affect basement membrane
normalization 2 days after initiation of DC101 therapy.
B: Perfused vessels (red) revealed an increase in collagenase IV activity
(green) near the vascular wall (arrows) at day 2 of DC101 therapy, com-
pared to control tumors. Extravascular collagenase IV activity was similar
in both groups.
C: GM6001, a broad-spectrum MMP inhibitor, completely abolished the
decrease of BM thickness induced by DC101.
Scale bars, 100 m (A and C), 20 m (B).
Figure 6. Time course and mechanisms of vascular normalization, illustrated*p  0.05, compared to control treated with rat nonspecific IgG plus Tie2
in schematic diagramsantibody (day 2).
A: VEGFR2 blockade produces a time window of morphological and func-
tional normalization of tumor vessels, which determines the tumor response
to radiotherapy.
B: Mechanisms of tumor vessel normalization by DC101. (i) Control tumors
It has previously been shown that chronic overexpression are characterized by tortuous, dilated blood vessels that lack tight pericyte
coverage and display a thickened, detached basement membrane. Theseof angiopoietin-1 starting during embryonic development in-
vascular abnormalities occur in the presence of excessive VEGF/VEGFR2creases the diameter of normal vessels (Thurston et al., 1999,
signaling. (ii) Within two days, VEGFR2 blockade can normalize BM morphol-2000), while transient Ang-1 overexpression in normal adult
ogy by activation of matrix metalloproteinases, increasing BM degradation.
vasculature (Thurston et al., 2000) or chronic Ang-1 overexpres- However, when Tie2 signaling is not activated, VEGFR2 blockade fails to
sion in tumors (Hawighorst et al., 2002) does not significantly improve other vascular abnormalities. This occurs when Tie2 is pharmaco-
logically inhibited (left), or when Ang-1 expression is low, as it is in siAng-1-change the vessel diameter. We show that transient Ang-1 over-
transfected tumors, or on day 8 of therapy (right). (iii) After VEGFR2 block-expression can reduce the vascular diameter of tumor vessels.
ade, the upregulation of Ang-1 in cancer cells and its binding to Tie2 are
The mechanism by which Ang-1 is upregulated after required for full vascular normalization.
VEGFR2 inhibition remains unknown. Ang-1 protein (as de-
tected by Western blot) was not changed in U87 cells in vitro
after exposure to DC101, which makes a direct effect of DC101
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on the tumor cells unlikely. Likewise, even though Ang-1 expres- Improved oxygenation significantly overcompensated for this
assumed radioprotection of endothelial cells by Ang-1, empha-sion was increased after reoxygenation of cultured astrocytes
(Song et al., 2002), we could not confirm a change in Ang-1 sizing once again that oxygen status dominates other factors
in determining the outcome of optimally combined therapy.protein in U87 glioma cells after 24 hr of hypoxia (0.5% oxygen)
and at different time points of reoxygenation (data not shown). The therapeutic gain achieved due to DC101 in the syner-
gistic combination group RT4 is substantial—from a tumorWewould therefore rather hypothesize that a paracrinemediator
that binds to adjacent tumor cells is produced by endothelial growth delay of 12.5 days for radiation alone to 21.7 days for
DC101RT4. To achieve a 21.7-day growth delay with radiationcells after VEGFR2 blockade, which, in turn, increases their
Ang-1 synthesis. alone, we would need to increase its total dose from 21 to 35–38
Gy (Kozin et al., 2001). The fact that we saw such a substantialOur study provides evidence that severe abnormalities of
the vascular basement membrane in glioma vessels are medi- increase in growth delay attests to the importance of tumor
oxygenation for radiation therapy (Hall, 2000).ated by VEGF signaling, since VEGFR2 blockade restores a
thinner, more closely attached BM monolayer by increasing The ability tomeasure tumor hypoxia in patients using nonin-
vasive imaging techniques may enable clinicians to optimizecollagen IV degradation byMMPs. The thick, disorganized base-
ment membrane in untreated tumors likely contributes to im- the combination of anti-VEGF treatment with radiation therapy.
Similar optimization strategies may also improve response topaired vascular function. It is plausible that a thickened sheet
of extracellular matrix can affect the extravasation of oxygen, chemotherapy. It is tempting to speculate that, if the time course
of vascular changes induced by VEGF blockade is taken intodrugs, and nutrients (Tsilibary, 2003; Farkas et al., 2000). In
contrast, subcutaneously implanted mammary carcinomas account, one might achieve a survival advantage greater than
the 5 months seen in the recent landmark clinical trial of combi-have incomplete vascular BM coverage. In these tumors,
VEGFR2 blockade increases BM coverage to near normal levels nation therapy (Hurwitz et al., 2004).
(Tong et al., 2004). These seemingly contradictory findings illus-
Experimental procedurestrate that the phenotype of the tumor vessel BM is dependent
on the localmicroenvironment. In both cases, VEGFR2blockade
Animal model and cell lines
appears to alter BM homeostasis, shifting the rates of BM syn- We implanted cranial windows into 8- to 10-week-old male nude mice as
thesis and degradation to produce a more normal BM pheno- previously described (Yuan et al., 1994). After one week, we implanted small
type. Our study not only sheds light on the mechanism of BM (0.2–0.3 mm diameter) fragments of U87 glioma tumors superficially into the
cerebral cortex under the cranial window at a depth of approximately 0.4thickening in gliomas but also demonstrates that it can be nor-
mm. Animals were anesthetized with ketamine/xylazine (100/10 mg/kg, i.m.)malized by disrupting the VEGF pathway.
for all experimental procedures. Intravenous injections were performed usingMost importantly, our results alleviate the concern that, by
a lateral tail vein. All cell lines were maintained in DMEM medium with 10%destroying blood vessels, antiangiogenic therapy will invariably
FBS. To obtain a stable short interfering hairpin RNA (siRNA) construct for
increase tumor hypoxia, leading to an increased resistance to silencing the angiopoietin-1 gene (siAng-1), we used oligos 5	-GAT CCG
radiation and increasedmetastatic potential (Bottaro and Liotta, GAA GAG TTG GAC ACC TTA TTC AAG AGA TAA GGT GTC CAA CTC
2003). On the contrary, we show that a properly timed VEGFR2 TTC CTT TTT TGG AAA-3	 and 5	-AGC TTT TCC AAA AAA GGA AGA GTT
GGA CAC CTT ATC TCT TGA ATA AGG TGT CCA ACT CTT CCG-3	 andblockade can transiently decrease hypoxia, opening up a win-
subcloned the product into a pSilencer 3.1-H1 hygro plasmid (Ambion). Thedow of opportunity to irradiate tumors more effectively.
pSilencer vector was stably transfected into U87 cells using LipofectamineIn fact, in our experiments, tumor oxygen status was the
2000 (Invitrogen), and transfected cells were selected with hygromycin. Allmain factor determining the efficacy of radiation. The recent
mouse experiments were approved by the Massachusetts General Hospital
study by Garcia-Barros et al. (2003) suggested that damage to Subcommittee on Research Animal Care.
tumor-associated endothelial cells plays a crucial role in the
outcome of radiation therapy. By blocking the main receptor Treatment protocol
For combination therapy, U87 gliomas constitutively expressing GFP werefor VEGF, a survival factor for tumor endothelial cells, DC101
monitored by intravital fluorescence microscopy. When grown to a diametermay enhance the damaging effect of radiation to tumor vessels
of 2–2.5 mm (defined as day 0), treatment was started with either the mono-(Dvorak, 2002; Ferrara et al., 2004; Kerbel and Folkman, 2002).
clonal VEGFR2-specific antibody DC101 (rat anti-mouse; ImClone Systems
However, the impact of this DC101-induced effect was not Inc.) or fractionated radiation. DC101 was injected i.p. at a dose of 40 mg/kg
dramatic and seemed to be independent of that caused by every 3 days, for a total of 3 injections.  radiation was given locally to the
radiation, as the tumor growth delay induced by DC101 was upper part of the brain in 3 daily fractions, 7 Gy each, at a dose rate of 4.6
Gy/min. When the treatment modalities were combined, radiotherapy wasvirtually identical when the antibodywas used alone or in combi-
started at one of 5 different time points relative to the first DC101 injection:nation with nonoptimal radiation schedules (RT1, RT2, RT3,
9 or 2 days before (R1 and R2 in Figure 1A, respectively), or 1, 4, or 7 daysRT5) compared to untreated controls or radiation monotherapy,
after (R3, R4, and R5, respectively). Therapeutic efficacy was evaluated byrespectively. Only whenDC101minimized tissue hypoxia during
measuring tumor growth delay (versus untreated control), as defined by the
RT4 did the combined effect become synergistic—that is, sig- time taken for tumors to double their initial diameter. Groups consisted of
nificantly greater than additive. In contrast, DC101-induced apo- 7–8 animals.
ptosis of tumor and vascular cells was similar on day 5 (corre- For all other studies, mice bearing U87 gliomas were injected with
DC101 or nonspecific rat IgG control antibody (Jackson ImmunoResearch)sponding to RT4) and on day 8 (corresponding to RT5);
i.p. at a dose of 40 mg/kg every third day for a maximum of three dosestherefore, it did not coincide with the synergistic effect of combi-
(days 0, 3, and 6). An additional control group with size-matched tumorsnation therapy that was exclusively observed for RT4. Interest-
received no specific treatment. When tumors were collected for histologicalingly enough, based on the literature (Kwak et al., 2000; Cho
analyses, treatment was scheduled to assure same tumor sizes (3–4 mm)
et al., 2004), one could argue that overexpression of Ang-1 per at the time of sacrifice. To block angiopoietin-1/Tie2 receptor signaling,
se during the normalization period should have decreased rather animals were injected either with 20 mg/kg anti-mouse Tie2 blocking anti-
body i.p. (R&D Systems) or with 125 nmol of the Tie2 blocking peptidethan increased the sensitivity of endothelial cells to radiation.
560 CANCER CELL : DECEMBER 2004
A R T I C L E
NLLMAAS (Tournaire et al., 2004) stereotactically into the tumor. For inhibi- time PCR, we quantified mRNA levels of various candidate molecules that
were identified by cDNA array analysis. Lux fluorogenic primers (Invitrogen)tion of MMPs, mice were injected i.p. with 150 g of the broad spectrum
MMP inhibitor GM 6001 (Ryss Lab). All agents were given 30 min after the specific for the mouse or human isoform of each mRNA species were de-
signed using Lux Online Primer Software (Invitrogen; primer sequences avail-mice received either DC101 or nonspecific rat IgG control antibody, and the
animals were sacrificed 2 or 5 days later. able on request). Quantitative RT-PCRs were performed on the ABI 7700
sequence detection system (Applied Biosystems). All experiments were per-
formed in duplicate, and a standard curve for the specific cDNA of interestAngiography by multiphoton laser scanning microscopy (MPLSM)
was run with every PCR reaction; amounts of cDNA are expressed relativeand microvascular permeability measurement
to this standard curve. Final quantification of each cDNA sample was relativeIn vivo MPLSM angiography of glioblastoma vessels was performed after
to human or mouse -actin according to the manufacturer’s instructionsi.v. injection of 0.1 ml 10 mg/ml FITC-Dextran (2M MW, Sigma) as described
(Applied Biosystems).previously (Brown et al., 2001). For each tumor, four adjacent images repre-
Ang-1 protein expression was determined by Western blot analysis.senting tumor vessels 
75 to 
200 m below the brain surface were ob-
Total protein from tumor xenografts was extracted in RIPA buffer, and 30tained through the cranial window at day
1, and the same regions identified
g of protein was separated on a 10% SDS-PAGE gel, transferred to PVDFby using landmarks of the overlaying pial vasculature were recorded at days
membrane, and incubated with anti-Ang1 antibody (1:1000, 4C overnight).1, 2, 5, and/or 8 (n  4 animals per group). Vessel length density, diameter,
Ang1 was visualized using the enhanced chemiluminescence kit (Amer-and volume were calculated for each vessel using NIH IMAGE 1.63 software
sham).(http://rsb.info.nih.gov/nih-image/), and means are expressed relative to the
value that was obtained in the same tumor region one day before initiation
Statistical analysisof treatment. The microvascular permeability to albumin was measured as
Data are expressed as mean  SEM. The principal statistical test was thepreviously described (Yuan et al., 1996).
Student’s t test (two tailed). p  0.05 was considered to be statistically
significant.Histology and immunostaining
Tumor-bearingmicewere injected i.v. with biotinylated lectin (Vector Labora-
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